A subgroup analysis of the VASALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/pcks9s-seen-driving-down-ldl-c-diabetes-2026a10009jb?src=rss
Author :
Publish date : 2026-03-29 18:16:00
Copyright for syndicated content belongs to the linked Source.
